#sttk hashtag - Bluesky

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights –First participants dosed in Phase 1 clinical trial of SL-325 in healthy volunteers – – Closed a private placement of up to $103 million in August 2025 to support advancement of SL-325 – – Appointments of Dan Baker, M.D., and Mona Ashiya, Ph.D. to the Board of Directors – AUSTIN, TX and DURHAM, NC,

4 months ago

#STTK Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Mika Uolamo

@mikauolamo.bsky.social

6 months ago

Miten ois #SAK, #STTK, #Akava ym., millos meillä?

3 0 0 0

Tiedonantaja

@tiedonantaja.bsky.social

6 months ago

STTK:n hallitus vaatii Gazan kansanmurhan lopettamista. Puheenjohtaja Antti Palola: ”Tyhjiä vetoomuksia ei enää tarvita.”
#sttk #solidaarisuus #Palestiina #Tiedonantaja
Tiedonantajan somejuttu 9.9.2025. Teksti: JP (Juha-Pekka) Väisänen. Kuva: Emma Grönqvist.

2 0 0 0

Jan-Olof Eriksson 🦋

@jaoler.fi

6 months ago

Työmarkkinajärjestöt valmistautuvat vaihtamaan johtajiaan – yksi lasikatto on menossa rikki Sotealan liitot Tehy ja Super kertoivat elokuun lopussa esittävänsä Else-Mai Kirvesniemeä STTK:n johtoon.

Go Else-Mai! #lasikatto #STTK #Tehy
suomenkuvalehti.fi/uutisviikko/...

1 1 0 0

Market Wire News

@marketwirenews.com

6 months ago

Just In: ( NASDAQ: #STTK ) PRISM Mid-Day Movers: Share Purchases and Wearables Innovation Drive Index Gains

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

6 months ago

Leading Indicators, Wednesday September 3, 2025 – Crystal Equity Research

Small-cap stocks gapping up in trading, Wed Sept 3rd - #URG #STI #SINT #AIHS #STTK #OPRA #LPTH #GEG #PKST #DRD - More: crystalequityresearch.com/leading-indi... - #smallcap

0 0 0 0

Tehy och SuPer föreslår Else-Mai Kirvesniemi som ordförande för STTK Tehy och SuPer föreslår vicehäradshövding Else-Mai Kirvesniemi som ordförande för STTK. Else-Mai Kirvesniemi har en stark kompetens om intressebevakningsuppgifter inom både den offentliga och den priv...

7 months ago

Tehy och SuPer föreslår vicehäradshövding Else-Mai Kirvesniemi som ordförande för @sttk.fi www.tehy.fi/sv/meddeland... #tehy #STTK #SuPerLiitto

1 0 0 0

Tehy and SuPer back Else-Mai Kirvesniemi for STTK President Tehy and SuPer nominate Master of Laws with court training Else-Mai Kirvesniemi for STTK president. Else-Mai Kirvesniemi has strong advocacy experience from both the public and private sectors. She is...

7 months ago

www.tehy.fi/en/bulletin/... #tehy #STTK #SuPerLiitto @sttk.fi

1 0 1 0

Tehy ja SuPer esittävät Else-Mai Kirvesniemeä STTK:n puheenjohtajaksi Tehy ja SuPer esittävät varatuomari Else-Mai Kirvesniemeä STTK:n puheenjohtajaksi. Else-Mai Kirvesniemellä on vahva osaaminen edunvalvontatehtävistä sekä julkiselta että yksityiseltä sektorilta. Hän t...

7 months ago

📣 Tehy ja SuPer esittävät Else-Mai Kirvesniemeä @sttk.fi:n puheenjohtajaksi!

– Lupaan olla käytettävissä tähän tärkeään tehtävään, Kirvesniemi sanoo.

STTK:n uusi puheenjohtaja valitaan 18. 12.2025.

#Tehy #SuPerliitto #ayliike #STTK

7 5 1 0

Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease Shattuck Labs (NASDAQ: STTK) announced that its Investigational New Drug (IND) application for SL-325, a potentially first-in-class DR3 antagonist antibody for treating Inflammatory Bowel Disease (IBD), is now in effect with the FDA.The company plans to initiate its Phase 1 clinical trial in Q3 2025, with expected completion in Q2 2026. The trial will be a randomized, double-blind, placebo-controlled study evaluating single and multiple ascending doses in healthy volunteers. The company's financial position is strengthened by cash reserves and anticipated proceeds of up to $103 million from a recent private placement, expected to fund operations into 2029.

7 months ago

#STTK Shattuck Labs Announces IND for SL-325 Is in Effect for the Treatment of Inflammatory Bowel Disease

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights Shattuck Labs (NASDAQ: STTK) reported Q2 2025 financial results and business updates. The company submitted an IND application for SL-325, their first-in-class DR3 blocking antibody for IBD treatment, with FDA clearance expected in Q3 2025. The Phase 1 clinical trial is set to begin in Q3 2025.Financial highlights include cash position of $50.5 million as of June 30, 2025, and an oversubscribed private placement expected to provide up to $103 million in additional funding. Q2 2025 showed improved financials with net loss of $12.5 million ($0.24 per share), compared to $21.6 million ($0.42 per share) in Q2 2024. The combined funding is expected to support operations into 2029.

7 months ago

#STTK Shattuck Labs Reports Second Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million Shattuck Labs (NASDAQ: STTK) has secured an oversubscribed private placement expected to raise up to $103 million in gross proceeds. The financing includes initial proceeds of $46 million and potential additional proceeds of $57 million from warrant exercises.The private placement, led by OrbiMed, involves issuing 15.2M shares of common stock and pre-funded warrants for 37.4M shares at $0.8677 per share, with accompanying warrants for 52.6M shares at $1.0846 exercise price. The proceeds will fund the clinical development of SL-325, a first-in-class DR3 blocking antibody for inflammatory bowel disease treatment, through multiple Phase 2 trials.The financing is contingent upon IND clearance for SL-325, with the combined proceeds expected to fund operations into 2029.

7 months ago

#STTK Shattuck Labs Announces Oversubscribed Private Placement of Up to Approximately $103 Million

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Lari Salo

@lariolas.bsky.social

9 months ago

Perussuomalaiset ammattiyhdistysliikkeeseen mukaan ja sisään Erittäin kannatettava asia, kunhan perussuomalaiset ovat tosissaan. Eivätkä lähde institutionaaliseen korruptioon mukaan. Alla olevassa kuvakoostessa konkreettinen esimerkkki Suomessa ay-liikkeen r…

Saksitaanko yksi järjestövallan arvojuurista pois?

"Perussuomalaiset ammattiyhdistysliikkeeseen mukaan ja sisään"
- Julkaistu: 23 syyskuun, 2011

suomi2017.wordpress.com/2011/09/23/p...

#peruspuurtajat #ayliike
#puoluekokous #Lahti
#työntekijät #raha
#kokoomus #EK #valta

#järjestövalta #SAK #STTK

0 0 1 0

Carmen DaVinleam

@carmendavinleam.bsky.social

9 months ago

Dark gritty thriller that Publishers Weekly calls a "Complex story of survival that unfold through the eyes of a street-smart protagonist, trapped in a dangerous web of lies." #sttk #tIttt #tmlore #thrillerbooks

2 0 0 0

ZJM

@zyanmvlik.bsky.social

10 months ago

taken in the room under the stairs #1YearOfRUTS 📸

#ZaynMalik - #STTK

4 2 0 0

Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights Shattuck Labs (NASDAQ: STTK) reported its Q1 2025 financial results and business updates. The company's lead product candidate, SL-325, a potential first-in-class DR3 antagonist antibody for inflammatory bowel disease (IBD), is progressing with an IND filing expected in Q3 2025. The company ended Q1 2025 with $60.9 million in cash, expected to fund operations into 2027. Financial results showed R&D expenses of $9.9 million (down from $16.3M in Q1 2024), G&A expenses of $4.5 million (down from $4.9M), and a net loss of $13.7 million ($0.27 per share). Preclinical studies of SL-325 demonstrated favorable safety profiles, full receptor occupancy at ≥1 mg/kg lasting >28 days, and potential differentiation from TL1A blocking antibodies.

11 months ago

#STTK Shattuck Labs Reports First Quarter 2025 Financial Results and Recent Business Highlights

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Biotech Spotlight: Shattuck Labs CEO Set for Major Investor Presentation at Needham Conference CEO Taylor Schreiber to showcase Shattuck's innovative TNF therapeutics pipeline at prestigious Needham Healthcare Conference. Live webcast available April 9.

11 months ago

#STTK Shattuck Labs Announces Participation in Upcoming 24th Annual Needham Virtual Healthcare Conference

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Erika Mattsson 🪷

@erikamattsson.bsky.social

1 year ago

SAK, Akava ja STTK: Hallitus haluaa työnantajille yksipuolisen oikeuden määritellä lakkojen rajat | STTK ry. Suojelutyötä koskeva sääntelyhanke on parhaillaan eduskunnan käsittelyssä.

SAK, Akava ja STTK: Hallitus haluaa työnantajille yksipuolisen oikeuden määritellä lakkojen rajat.

#Suojelutyö #Hätätyö #Akava #SAK #STTK
www.sttinfo.fi/tiedote/7102...

3 1 0 0

Shattuck Labs Pivots Strategy: New IBD Drug Shows Promise as Company Reports $73M War Chest Shattuck advances first-in-class IBD treatment while maintaining strong $73M cash runway into 2027. Key milestone: SL-325 IND filing expected Q3 2025. Full analysis inside.

1 year ago

#STTK Shattuck Labs Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Highlights

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Revolutionary IBD Drug Development: Shattuck Labs Unveils Critical DR3 Antibody Results at ECCO 2025 Shattuck Labs to showcase breakthrough SL-325 toxicology study results for inflammatory bowel disease treatment at prestigious ECCO Congress in Berlin.

1 year ago

#STTK Shattuck Labs Announces Oral Presentation at Upcoming 20th Congress of European Crohn’s and Colitis Organization (ECCO) in Inflammatory Bowel Diseases 2025

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

Pivotal IBD Drug Development: Shattuck Labs Reveals SL-325 Data at Major Crohn's Congress Shattuck Labs announces poster presentation of SL-325, their novel DR3-targeted antibody for IBD treatment, at the 2025 Crohn's and Colitis Congress in San Francisco.

1 year ago

#STTK Shattuck Labs Announces Poster Presentation at Upcoming 2025 Crohn’s and Colitis Congress

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0

1 year ago

Ota seurantaan! ✨ #Tehy #STTK

4 2 0 0

Shattuck Labs CEO to Present at J.P. Morgan Healthcare Conference 2025 Shattuck Labs announces participation in the 43rd Annual J.P. Morgan Healthcare Conference, with CEO Dr. Taylor Schreiber scheduled for corporate update on January 16.

1 year ago

#STTK Shattuck Labs Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

www.stocktitan.net/news/STTK/shattuck-labs-...

0 0 0 0